Holds one active US DMF and one valid CEP for cisplatin, filing since 2014. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.
Holds one active US DMF and one valid CEP for cisplatin, filing since 2010. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 7 markets.
Holds 2 active US DMFs and one valid CEP for cisplatin, filing since 2008. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 13 markets.
Holds 4 valid CEPs for cisplatin, filing since 2021. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Holds one active US DMF for cisplatin, filing since 1986. Its 2022 FDA inspection closed as VAI.
Holds one active US DMF for cisplatin, filing since 2014. Its 2018 FDA inspection closed as VAI.
Holds one active US DMF for cisplatin, filing since 1992.
Holds one valid CEP for cisplatin, filing since 2024. Its GMP is recognised in 1 market.
Registered with SFDA (Saudi Arabia) for cisplatin. Its GMP is recognised in 1 market.
Its 2025 FDA inspection closed as OAI.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Contract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free